Cullinan Therapeutics (CGEM) Enterprise Value (2020 - 2026)

Cullinan Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$628.7 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 18.41% year-over-year to -$628.7 million in Q1 2026; TTM through Mar 2026 was -$628.7 million, a 18.41% decrease from a year earlier, with the FY2025 full-year figure at -$377.9 million, up 5.28% from the prior year.
• Enterprise Value eased to -$628.7 million in Q1 2026 per CGEM's latest filing, from -$377.9 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$265.5 million in Q2 2025 and bottomed at -$1.1 billion in Q3 2024.
• The 5-year median for Enterprise Value is -$552.9 million (2022), against an average of -$585.0 million.
• Across the five-year window, Enterprise Value tumbled 160.21% in 2022 and jumped 59.93% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$467.3 million in 2022, then increased by 0.09% to -$466.9 million in 2023, then advanced by 14.54% to -$399.0 million in 2024, then advanced by 5.28% to -$377.9 million in 2025, then slumped by 66.37% to -$628.7 million in 2026.
• Per Business Quant, the three latest CGEM Enterprise Value figures stand at -$628.7 million (Q1 2026), -$377.9 million (Q4 2025), and -$561.9 million (Q3 2025).